EUVIMEDEUVIMED entdecken
Crossref

Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry

Jürgen C Becker iD, Seyed Hamidreza Mahmoudpour, Dirk Schadendorf iD, Ulrike Leiter, Friedegund Meier, Rudolf Herbst, Stephan Grabbe iD, Christoffer Gebhardt iD, Fabian Ziller, Claudia Pföhler, Peter Mohr, Lisa Zimmer und 7 weitere

British Journal of Dermatology · 10.10.2026

DOI: 10.1093/bjd/ljag445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 10.10.2026. Verfasst von Jürgen C Becker und 18 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Translational Skin Cancer Research and Dermatology, University Medicine Essen, Essen, Germany. Die Arbeit nennt 8 Literaturangaben. Gefördert von: Merck.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study observed the real-world outcomes with avelumab treatment in patients with Merkel cell carcinoma (MCC) in Germany by immunocompromised status. Objective response rates with avelumab as first-line treatment were similar in immunocompromised and immunocompetent patients; however, long-term survival was shorter in the immunocompromised subgroup. Rates of avelumab-related adverse drug reactions were comparable between the subgroups. These findings demonstrate the clinical activity and safety of avelumab in both immunocompetent and immunocompromised patients with MCC.

Autor:innen und Institutionen

  • Departments of Translational Skin Cancer Research and Dermatology, University Medicine Essen, Essen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Merck Healthcare KGaA, Darmstadt, Germany.
  • Department of Dermatology, University Hospital Essen; German Cancer Consortium, Partner Site Essen; National Center for Tumor Diseases (NCT) West, Campus Essen, Essen, Germany.
  • Research Alliance Ruhr - Research Center One Health, University of Duisburg-Essen, Essen, Germany.
  • Department of Dermatology, Center for Dermato-Oncology, Eberhard Karls University of Tübingen, Tübingen, Germany.

ORCID-Profile: Jürgen C Becker, Dirk Schadendorf, Stephan Grabbe, Christoffer Gebhardt

Förderung

  • Merck

Zitieren

APA

Becker, J. C., Mahmoudpour, S. H., Schadendorf, D., Leiter, U., Meier, F., Herbst, R., Grabbe, S., Gebhardt, C., Ziller, F., Pföhler, C., Mohr, P., Zimmer, L., Boutmy, E., Oksen, D., Kearney, M., Ruth, K., Hoff, S., Shlaen, M., & Ugurel, S. (2026). Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag445

Vancouver

Becker JC, Mahmoudpour SH, Schadendorf D, Leiter U, Meier F, Herbst R, et al. Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag445

BibTeX
@article{Becker2026,
  author = {Becker, Jürgen C and Mahmoudpour, Seyed Hamidreza and Schadendorf, Dirk and Leiter, Ulrike and Meier, Friedegund and Herbst, Rudolf and Grabbe, Stephan and Gebhardt, Christoffer and Ziller, Fabian and Pföhler, Claudia and Mohr, Peter and Zimmer, Lisa and Boutmy, Emmanuelle and Oksen, Dina and Kearney, Mairead and Ruth, Katia and Hoff, Sebastian and Shlaen, Margarita and Ugurel, Selma},
  title = {Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag445}
}
Kostenlos starten →